aTyr Pharma, Inc. Stock News

ATYR Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Oct. 14, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. Prominent shareholders rights firm H...

SAN FRANCISCO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial.

NEW YORK--(BUSINESS WIRE)---- $ATYR #ATYR--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a le...

LOS ANGELES--(BUSINESS WIRE)--aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR.

NEW YORK , Oct. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). aTyr is a clinical stage biotechnology company. For more information, submit a for...

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options

SAN FRANCISCO , Oct. 9, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial. Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims.